therapeutics targeting cell adhesion

  • Home
  • About Us
  • Our Team
  • Technology
  • Unmet Need
  • Contact Us
  • News
  • More
    • Home
    • About Us
    • Our Team
    • Technology
    • Unmet Need
    • Contact Us
    • News
  • Home
  • About Us
  • Our Team
  • Technology
  • Unmet Need
  • Contact Us
  • News

COrporate Profile

Zonula is a privately held biotechnology company located in Montreal, Quebec, Canada. The company discovers and develops therapies for the treatment of fibrotic diseases.

The Zonula Difference

Fibrosis is the process leading to the accumulation of collagen-based scars within tissues. Targeting cell adhesion represents a new approach to preventing fibrosis. Zonula is developing inhibitors of cell adhesion that turn off collagen production by cells called fibroblasts (shown in the picture).  


Fibroblast adhesion is governed by N-cadherin, which can be thought of as a biological glue. Zonula's N-cadherin inhibitors disrupt fibroblast adhesion and collagen production by these cells.

n-cadherin controls fibrosis

COMPETITIVE ADVANTAGE OVER EXISTING FIBROSIS THERAPIES

Zonula's N-cadherin inhibitors:

  1. turn off the master switch for fibrosis
  2. are small molecules that can be easily manufactured
  3. can be orally administered
  4. have a low cost to manufacture
  5. can be used to treat all types of fibrosis-dependent diseases

zonula pipeline


Copyright © 2023 Zonula Inc. - All Rights Reserved.

Powered by GoDaddy Website Builder